Hepatitis B--molecular variants with clinical significance?

Area of Science:

• Hepatology
• Virology
• Molecular Biology

Background:

• Hepatitis B virus (HBV) mutations can alter viral protein synthesis and clinical presentation.
• Hepatitis B e antigen (HBeAg) is a secreted viral protein typically associated with active HBV replication.
• Premature stop codons in the pre-core region are common HBV mutations.

Purpose of the Study:

• To investigate the clinical significance of HBV mutations, specifically those affecting HBeAg production.
• To understand the association between HBeAg-negative HBV mutants and disease severity.
• To explore the role of HBeAg in immune tolerance versus active immune response.

Main Methods:

• Analysis of HBV DNA and serological markers (HBeAg, anti-HBe) in patients with various hepatitis B infection stages.
• Identification of HBV pre-core mutations, including single nucleotide substitutions leading to premature stop codons.
• Correlation of mutant HBV detection with clinical outcomes such as acute hepatitis B, chronic hepatitis B, and fulminant hepatitis B.

Main Results:

• A common mutation involves a single nucleotide substitution creating a premature stop codon in the pre-core region, preventing HBeAg synthesis.
• HBeAg-negative mutant HBV was detected in patients with high viral DNA levels but lacking HBeAg, and during HBeAg to anti-HBe seroconversion.
• Mutant HBV was absent in HBeAg-positive chronic hepatitis B and uncomplicated acute hepatitis B, but present in fulminant hepatitis B cases lacking both HBeAg and anti-HBe.

Conclusions:

• The lack of HBeAg due to pre-core mutations may indicate a more severe form of acute hepatitis B.
• Serum HBeAg presence might be associated with immunologic tolerance.
• HBeAg clearance or absence, particularly in mutant forms, may correlate with an active immune response during HBV infection.